Indiana Biosciences Research Institute
An independent translational research institute that convenes academic, industry and public partners to develop patient-informed solutions for diabetes, cardiometabolic disease, neurodegeneration and related areas. Operates collaborative research centers and core facilities focused on data science, bioanalytical technologies, single-cell analysis, and pharmaceutical biotechnology to advance discovery, preclinical candidate development and early-stage translational projects.
Industries
N/A
Nr. of Employees
small (1-50)
Indiana Biosciences Research Institute
1210 Waterway Blvd., Ste. 2000, Indianapolis, IN 46202
Products
Open toxicogenomics web portal
A web-accessible analytics portal that integrates mechanistic and toxicogenomic study results to predict longer-term toxicity from short-duration gene expression changes.
Single-cell rare-cell analysis platform (research prototype)
A research-stage platform combining microfluidic sample handling, nanoparticle chemistries and mass spectrometric readouts to detect and analyze rare cells from whole blood and clinical samples.
Open toxicogenomics web portal
A web-accessible analytics portal that integrates mechanistic and toxicogenomic study results to predict longer-term toxicity from short-duration gene expression changes.
Single-cell rare-cell analysis platform (research prototype)
A research-stage platform combining microfluidic sample handling, nanoparticle chemistries and mass spectrometric readouts to detect and analyze rare cells from whole blood and clinical samples.
Services
Peptide production using in-house synthesis instrumentation to support discovery-stage chemistry and screening.
Shared analytics platform for integrating toxicogenomic datasets and mechanistic study results to accelerate early compound safety decisions.
Development and validation of single-cell assays and rare-cell detection workflows combining microfluidics, nanoparticle reagents and mass spectrometry.
Peptide production using in-house synthesis instrumentation to support discovery-stage chemistry and screening.
Shared analytics platform for integrating toxicogenomic datasets and mechanistic study results to accelerate early compound safety decisions.
Development and validation of single-cell assays and rare-cell detection workflows combining microfluidics, nanoparticle reagents and mass spectrometry.
Expertise Areas
- Translational research and industry-academic partnerships
- Real-world data analytics and clinical informatics
- Toxicogenomics and predictive toxicology
- Single-cell analytics and rare-cell detection
Key Technologies
- Mass spectrometry
- Microfluidics
- Single-cell analysis
- BioMEMs (microelectromechanical systems)
News & Updates
Collaboration using EHR-derived real-world patient data to improve prediction of diabetes-related chronic kidney disease.
Publication detailing a novel open-access web portal for integrating mechanistic and toxicogenomic study results (platform used for early risk assessment).
Peer-reviewed article demonstrating a single-cell detection platform capable of identifying rare cells from whole blood samples using microfluidics and mass spectrometry.
Public release and adoption efforts for a toxicogenomics platform to accelerate early risk assessment in drug development.
Development milestones achieved for a BioMEMs point-of-care analyzer and a single-cell SIERRA reagent platform ahead of schedule.
Collaboration using EHR-derived real-world patient data to improve prediction of diabetes-related chronic kidney disease.
Publication detailing a novel open-access web portal for integrating mechanistic and toxicogenomic study results (platform used for early risk assessment).
Peer-reviewed article demonstrating a single-cell detection platform capable of identifying rare cells from whole blood samples using microfluidics and mass spectrometry.
Public release and adoption efforts for a toxicogenomics platform to accelerate early risk assessment in drug development.
Development milestones achieved for a BioMEMs point-of-care analyzer and a single-cell SIERRA reagent platform ahead of schedule.